Search results
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock...
Benzinga via Yahoo Finance· 11 months agoZai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) presented results from the phase...
Why Is Cancer Focused Novocure Stock Trading Higher Today?
Benzinga via Yahoo Finance· 4 months agoNovocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval...
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoImage source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2024 Earnings Call May 02, 2024, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers...
Why NovoCure Stock Soared 18.3% This Week
Motley Fool via Yahoo Finance· 1 month agoShares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging...
Will Novocure Stock Sink or Soar in 2023?
Motley Fool· 1 year agoNovocure (NASDAQ: NVCR) announced good news earlier this month from a late-stage study evaluating its Tumor-Treating Fields (TTFields) therapy in...
Why NovoCure Stock Is Crashing Today
Motley Fool· 11 months agoWhat happened Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company...
NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 months agoNovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript October 26, 2023 NovoCure Limited...
Novocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer Patients
Benzinga via Yahoo Finance· 1 year agoZai Lab Limited (NASDAQ: ZLAB) and Novocure Ltd (NASDAQ: NVCR) announced that the LUNAR study met...
Novocure Stock: Bull vs. Bear
Motley Fool· 1 year agoMany companies like to claim that they have revolutionary, game-changing products. Few live up to the hype. Novocure (NASDAQ: NVCR) could be an...
2 Potentially Explosive Stocks to Buy in November
Motley Fool· 2 years agoNovocure (NASDAQ: NVCR) is handily beating the S&P 500 so far in 2022. The company is currently evaluating its tumor treating fields (TTFields) therapy...
